3-甲基吗啉 | 42185-06-8

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 3-甲基吗啉
• 英文名称: 3-methylmorpholine
• CAS: 42185-06-8
• 化学式: C₅H₁₁NO
• mdl: MFCD09054773
• 分子量: 101.148
• InChiKey: SFWWGMKXCYLZEG-UHFFFAOYSA-N

物化性质

• 沸点：
  133-134 °C
• 密度：
  0.9591 g/cm3(Temp: 16 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 包装等级：
  II
• 危险类别：
  8,3
• 危险性防范说明：
  P501,P240,P210,P233,P243,P241,P242,P264,P280,P370+P378,P303+P361+P353,P301+P330+P331,P363,P304+P340+P310,P305+P351+P338+P310,P403+P235,P405
• 危险品运输编号：
  2734
• 危险性描述：
  H314,H226

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Methylmorpholine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Methylmorpholine
CAS number: 42185-06-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H11NO
Molecular weight: 101.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-甲基吗啉 在 Iron(III) nitrate nonahydrate 、 四丁基高氯酸铵 作用下， 以 乙腈 为溶剂， 以83%的产率得到N-nitroso-3-methylmorpholine
  参考文献：
  名称：

  通过双自由基偶联反应对仲胺进行电化学非酸性N-亚硝化/ N-硝化

  摘要：

  在仲胺的N-H键为Fe的游离酸-N-亚硝化/硝化（NO 3）3  ⋅9H 2 O为通过电催化自由基偶合反应的亚硝基/硝基源被开发。环状脂肪胺和N-杂芳族化合物分别在温和的条件下进行N-亚硝化和N-硝化。控制和竞争实验，以及动力学研究，证明了的N-亚硝化和N-硝化涉及涉及Ñ两个不同的自由基反应途径+和N 。部首。此外，电催化方法使电极上的NH键优先活化，因此对特定N原子具有高选择性。最后，该策略具有广泛的应用范围，并提供了一种绿色且直接的方法来以高收率生成有用的N-亚硝基/硝基化合物。

  DOI：

  10.1002/adsc.202000267
• 作为产物：
  描述：

  1-(2-aminoethoxy)propan-2-ol 在 chloro(p-cymene)[(S)-2-(2-(diphenylphosphanyl)-phenyl)-4-phenyl-4,5-dihydrooxazole]ruthenium(II) chloride 、 potassium tert-butylate 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以86%的产率得到3-甲基吗啉
  参考文献：
  名称：

  借用氢方法论钌催化仲醇胺化

  摘要：

  一种新的钌络合物通过借用的氢途径催化伯醇和仲醇的胺化以及二醇的区域选择性单次或连续的二氨基化。氨基醇，二醇和二胺的新的分子内和分子间环化的几种变化导致杂环系统。

  DOI：

  10.1021/acscatal.6b00175

文献信息

• [EN] INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING<br/>[FR] INHIBITEURS DE LA LIAISON PROTÉINE WDR5-PROTÉINE
  申请人：ONTARIO INST FOR CANCER RES (OICR)

  公开号：WO2017147700A1

  公开（公告）日：2017-09-08

  The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

  本申请涉及到Formula I的化合物：包括这些化合物的化合物及其用途，例如作为治疗由于抑制WDR5蛋白与其结合伙伴之间结合而介导或可治疗的疾病、疾病或症状的药物。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF
  申请人：FUJIFILM Corporation

  公开号：US20150322063A1

  公开（公告）日：2015-11-12

  A compound represented by Formula [1] (in the formula, Z 1 represents N, CH, or the like; X 1 represents NH or the like; R 1 represents a heteroaryl group or the like; each of R 2 , R 3 , and R 4 represents a hydrogen atom, a halogen atom, an alkoxy group, or the like; and R 5 represents a heteroaryl group or the like) or salt thereof.

  由式[1]表示的化合物（在该式中，Z表示N、CH或类似物；X表示NH或类似物；R表示杂环烷基或类似物；R2、R3和R4中的每一个表示氢原子、卤原子、烷氧基或类似物；R5表示杂环烷基或类似物）或其盐。
• [EN] THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS<br/>[FR] THIÉNO[3,2-C]PYRIDIN-4(5H)-ONES UTILES COMME INHIBITEURS DE BET
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2014078257A1

  公开（公告）日：2014-05-22

  Thienopyridone compounds of formula (I) or a salt thereof, pharmaceutical compositions containing such compounds and their use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.

  噻诺吡啶酮化合物或其盐，含有该化合物的药物组合物及其在治疗中的用途，特别是在溴结构域抑制剂用于治疗的疾病或症状中。
• Visible‐Light‐Mediated Aerobic Oxidative C( <i>sp</i> ^<i>3</i> )−C( <i>sp</i> ^<i>3</i> ) Bond Cleavage of Morpholine Derivatives Using 4CzIPN as a Photocatalyst
  作者：Chun‐Lin Dong、Lan‐Qian Huang、Zhi Guan、Chu‐Sheng Huang、Yan‐Hong He

  DOI：10.1002/adsc.202100455

  日期：2021.8.3

  Herein, a metal-free strategy for the aerobic oxidative cleavage of the inert C(sp3)−C(sp3) bond was developed. Deconstruction of morpholine derivatives was conducted using visible light as an energy source and O2 as an oxidant under mild conditions. This procedure demonstrated suitable selectivity and functional group tolerance. Moreover, a possible mechanism involving a radical process was proposed

  在此，开发了一种用于惰性 C( sp 3 )-C( sp 3 ) 键有氧氧化裂解的无金属策略。以可见光为能源，O 2为氧化剂，在温和条件下进行吗啉衍生物的解构。该程序证明了合适的选择性和官能团耐受性。此外，基于一系列机制探索和控制实验，提出了涉及激进过程的可能机制。
• [EN] 6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4] TRIAZOLO [4, 3 -A] PYRADINES AS TYROSINE KINASE<br/>[FR] 3-(QUINOLIN-6-YLTHIO)-[1,2,4]TRIAZOLO[4,3-A]PYRADINES SUBSTITUÉES EN POSITION 6 À ACTIVITÉ TYROSINE KINASE
  申请人：NOVARTIS AG

  公开号：WO2013038362A1

  公开（公告）日：2013-03-21

  The invention relates to compounds of formula (I) and salts thereof: Formula (I) wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

  该发明涉及公式(I)化合物及其盐：公式(I)其中的取代基如说明书中所定义；用于治疗人体或动物体的公式(I)化合物，特别是针对c-Met酪氨酸激酶介导的疾病或状况；使用公式(I)化合物来制造治疗此类疾病的药物；包含公式(I)化合物的药物组合物，可选地与联合用药伙伴一起使用，以及制备公式(I)化合物的方法。

表征谱图